Home LiteratureArticle Details
PMID: 24638136 Published · ppublish English Journal Article Comment

Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.

Nature reviews. Neurology ·Vol. 10 ·No. 4 ·2014-04-00 ·Pages 179

Malkki H

Abstract

暂无摘要

MeSH Terms
Angiogenesis Inhibitors/therapeutic use Antibodies, Monoclonal, Humanized/therapeutic use Brain Neoplasms/drug therapy Dacarbazine/analogs & derivatives Female Glioblastoma/drug therapy Humans Male
Chemicals
Angiogenesis Inhibitors Antibodies, Monoclonal, Humanized Dacarbazine
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Malkki Hemi
References (2)
2 references, click to expand
  1. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
    N Engl J Med. 2014 Feb 20;370(8):699-708 PMID: 24552317
  2. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    N Engl J Med. 2014 Feb 20;370(8):709-22 PMID: 24552318
Article Info
Journal
Nature reviews. Neurology
Abbr.
Nat Rev Neurol
ISSN
1759-4766
DOI
10.1038/nrneurol.2014.47
Published
2014-04-00
Epub
2014-00-18
Pages
179
Language
English
Region
England
NLM ID
101500072
Subset
IM
Corrections
CommentOn
PMID: 24552317
CommentOn
PMID: 24552318
External Links
PubMed source DOI: 10.1038/nrneurol.2014.47 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2